Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 116

Sort by

Sort Order Select

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Blood (2024) 144 (Supplement 1): 7236.

https://doi.org/10.1182/blood-2024-197883

Published: 2024

Journal Articles

Promising Safety and Efficacy of Eque-Cel Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients: Primary Real World Data from a Single Center

Yan Xu, Gang An, Wei LIU, Qi Wang, Yi Wang, Shuaishuai Zhang, Wenjie Xiong, Tengteng Yu, Mingwei Fu, Shuhua Yi, Lugui Qiu, Dehui Zou

Blood (2024) 144 (Supplement 1): 7228.

https://doi.org/10.1182/blood-2024-209328

Published: 2024

Journal Articles

Phase II Clinical Study of Zanubrutinib Combined with Bendamustine and Rituximab (ZBR) for Time-Limited Treatment of Waldenstrom Macroglobulinemia

Xiong Wenjie, Yuting Yan, Ying Yu, Tingyu Wang, Wei Liu, Gang An, Weiwei Sui, Wenyang Huang, Dehui Zou, Lu-Gui Qiu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 6324.

https://doi.org/10.1182/blood-2024-198882

Published: 2024

Journal Articles

A Phase Ib/II Study of Trovocabtagene Autoleucel (C-CAR088), an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

Gang An, Yan Xu, Shuhua Yi, Rui Lyu, Jiaqi Huang, Wensi Li, Yiran Zhang, Liping Lan, Lugui Qiu

Blood (2024) 144 (Supplement 1): 7235.

https://doi.org/10.1182/blood-2024-194774

Published: 2024

Journal Articles

Single-Cell Multi-Omics Analysis Reveals Heterogeneity of Malignant Plasma Cell during Progression of Multiple Myeloma

Fangshuo Feng, Hao Sun, Xiaoyu Zhang, Xiyue Sun, Tengteng Yu, Haiqing Xiong, Gang An, Lu-Gui Qiu, Mu Hao

Blood (2024) 144 (Supplement 1): 6845.

https://doi.org/10.1182/blood-2024-203100

Published: 2024

Journal Articles

Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia

Xiong Wenjie, Yuting Yan, Tingyu Wang, Weiwei Sui, Ying Yu, Tengteng Yu, Rui Lyu, Wei Liu, Huimin Liu, Gang An, Wenyang Huang, Dehui Zou, Lu-Gui Qiu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 1648.

https://doi.org/10.1182/blood-2024-198864

Published: 2024

Journal Articles

T(11;14) with Multiple Myeloma: Standard Risk Survival but Slow and Poor Response

Yuntong Liu, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 4709.

https://doi.org/10.1182/blood-2024-200904

Published: 2024

Journal Articles

TENT5C As a Target of Chromatin Remodeler SMARCA2 Participates BTK Inhibitor Resistance in Mantle Cell Lymphoma By Regulating ATP Metabolism

Yuting Yan, Dandan Shan, Ying Yu, Weihao Chen, Xinyi Zhang, Xiong Wenjie, Tingyu Wang, Mu Hao, Gang An, Lu-Gui Qiu, Zhen Yu, Shuhua Yi

Blood (2024) 144 (Supplement 1): 832.

https://doi.org/10.1182/blood-2024-201941

Published: 2024

Journal Articles

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Blood (2024) 144 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2024-201476

Published: 2024

Journal Articles

Evaluation of D-Vrd Induction/Consolidation Therapy with MRD-Adapted Maintenance in Transplant-Eligible NDMM Patients with Double-Hit Cytogenetic Abnormality (MMY2094)

Chenxing Du, Shuaishuai Zhang, Lugui Qiu, Gang An, Wenqiang Yan, Jian Cui, Weiwei Sui, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou

Blood (2024) 144 (Supplement 1): 7068.

https://doi.org/10.1182/blood-2024-207775

Published: 2024

Journal Articles

Analysis of Diagnosis and Treatment Pattern for Newly Diagnosed Multiple Myeloma in China over 20 Years

Jingyu Xu, Yuntong Liu, Wenqiang Yan, Lingna Li, Rui Lyu, Chenxing DU, Weiwei Sui, Lugui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 6917.

https://doi.org/10.1182/blood-2024-201167

Published: 2024

Journal Articles

Real-World Patient Characteristics and Outcomes in China Multiple Myeloma Patients with Unmet Needs

Jian Cui, Dan Shen, Gang Liu, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 6908.

https://doi.org/10.1182/blood-2024-198949

Published: 2024

Journal Articles

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Gang An, Zhuogang Liu, Jie Jin, Zhen Cai, Wei Li, Zhongjun Xia, Xinan Cen, Yu Hu, Jian-Qing Mi, Hongmei Jing, Rong Zhan, Xiaoyan Qu, Xin Du, Dan Gao, Liang Zhao, Lugui Qiu

Blood (2024) 144 (Supplement 1): 7055.

https://doi.org/10.1182/blood-2024-199908

Published: 2024

Journal Articles

Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Blood (2024) 144 (Supplement 1): 4349.

https://doi.org/10.1182/blood-2024-202324

Published: 2024

Journal Articles

Anti-CD3/B-Cell Maturation Antigen Bispecific Antibody CM336 in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase I/II Study

Gang An, Zhongxia Huang, Aibin Liang, Baijun Fang, Hongmei Jing, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 3377.

https://doi.org/10.1182/blood-2024-206742

Published: 2024

Journal Articles

Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes

Blood (2024) 144 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2024-202457

Published: 2024

Journal Articles

Dissecting the Interplay between Primary Central Nervous System Lymphoma Cells and the Microenvironment Using Single-Cell Transcriptomic Analysis

Qianru Zhang, Wenqiang Yan, Lu Sun, Guoqing Han, Qiaoli Wu, Yiran Cui, Bolin Liu, Feng Zhang, Ke Pu, Mingchao Zhang, Xiaobing Zhang, Lugui Qiu, Qingguo Li, Gang An, Yuxuan Liu

Blood (2024) 144 (Supplement 1): 1590.

https://doi.org/10.1182/blood-2024-202680

Published: 2024

Journal Articles

Clinical Implications of Residual Immunophenotypically Normal Plasma Cells within Bone Marrow at Various Disease Stages in Multiple Myeloma

Wenqiang Yan, Lihui Shi, Jingyu Xu, Lingna Li, Jian Cui, Chenxing DU, Tengteng Yu, Shuaishuai Zhang, Rui Lv, Weiwei Sui, Shuhui Deng, Yan Xu, Dehui Zou, Lu-Gui Qiu, Mu Hao, Gang An

Blood (2024) 144 (Supplement 1): 1932.

https://doi.org/10.1182/blood-2024-199452

Published: 2024

Journal Articles

MBS314, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x B-Cell Maturation Antigen (BCMA) x CD3 Trispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM): Preliminary Results from a Phase Ⅰ, First-in-Human, Open-Label, Dose Escalation Study

Gang An, Lijie Xing, Wenming Chen, Yan Zhang, Wen Gao, Lu-Gui Qiu, Guojin Wu, Jinying Ning, Min Wei, Feng Li

Blood (2024) 144 (Supplement 1): 3356.

https://doi.org/10.1182/blood-2024-199423

Published: 2024

Journal Articles

Critical Roles of LILRB4 in Promoting PIM Kinase Mediated Cell Proliferation and Tumorigenesis in Multiple Myeloma

Yijie Wang, Jingyuan Ma, Xiyue Sun, Lixin Gong, Lanting Liu, Gang An, Lu-Gui Qiu, Mu Hao

Blood (2024) 144 (Supplement 1): 3262.

https://doi.org/10.1182/blood-2024-202920

Published: 2024

NARROW

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients

Promising Safety and Efficacy of Eque-Cel Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients: Primary Real World Data from a Single Center

Phase II Clinical Study of Zanubrutinib Combined with Bendamustine and Rituximab (ZBR) for Time-Limited Treatment of Waldenstrom Macroglobulinemia

A Phase Ib/II Study of Trovocabtagene Autoleucel (C-CAR088), an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

Single-Cell Multi-Omics Analysis Reveals Heterogeneity of Malignant Plasma Cell during Progression of Multiple Myeloma

Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia

T(11;14) with Multiple Myeloma: Standard Risk Survival but Slow and Poor Response

TENT5C As a Target of Chromatin Remodeler SMARCA2 Participates BTK Inhibitor Resistance in Mantle Cell Lymphoma By Regulating ATP Metabolism

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Evaluation of D-Vrd Induction/Consolidation Therapy with MRD-Adapted Maintenance in Transplant-Eligible NDMM Patients with Double-Hit Cytogenetic Abnormality (MMY2094)

Analysis of Diagnosis and Treatment Pattern for Newly Diagnosed Multiple Myeloma in China over 20 Years

Real-World Patient Characteristics and Outcomes in China Multiple Myeloma Patients with Unmet Needs

Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis

Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Anti-CD3/B-Cell Maturation Antigen Bispecific Antibody CM336 in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase I/II Study

Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes

Dissecting the Interplay between Primary Central Nervous System Lymphoma Cells and the Microenvironment Using Single-Cell Transcriptomic Analysis

Clinical Implications of Residual Immunophenotypically Normal Plasma Cells within Bone Marrow at Various Disease Stages in Multiple Myeloma

MBS314, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x B-Cell Maturation Antigen (BCMA) x CD3 Trispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM): Preliminary Results from a Phase Ⅰ, First-in-Human, Open-Label, Dose Escalation Study

Critical Roles of LILRB4 in Promoting PIM Kinase Mediated Cell Proliferation and Tumorigenesis in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only